Login to Your Account


FDA finalizes a 15-year-old sameness map for orphan MAbs

By Mari Serebrov
Washington Editor

Tuesday, April 22, 2014

Drugmakers hoping to compete with a monoclonal antibody (MAb) granted a seven-year orphan drug exclusivity have final guidance on what they need to do to differentiate their MAbs to get around the exclusivity. 

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription